These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 3123242

  • 1. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.
    Wien Klin Wochenschr; 1979 May 11; 91(10):332-7. PubMed ID: 452602
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
    Lieberman A, Estey E, Gopinathan G, Ohashi T, Sauter A, Goldstein M.
    Neurology; 1978 Sep 11; 28(9 Pt 1):964-8. PubMed ID: 567768
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
    Crevoisier C, Hoevels B, Zürcher G, Da Prada M.
    Eur Neurol; 1987 Sep 11; 27 Suppl 1():36-46. PubMed ID: 3428308
    [Abstract] [Full Text] [Related]

  • 7. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
    Boomsma F, Meerwaldt JD, Man in't Veld AJ, Hovestadt A, Schalekamp MA.
    J Neurol; 1989 May 11; 236(4):223-30. PubMed ID: 2760634
    [Abstract] [Full Text] [Related]

  • 8. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH, Lees AJ, Stern GM.
    Eur Neurol; 1987 May 11; 27 Suppl 1():93-7. PubMed ID: 3322842
    [Abstract] [Full Text] [Related]

  • 9. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A, Eckernäs SA, Collin C, Ling-Andersson A, Tiger G, Nilsson M.
    Eur Neurol; 1992 May 11; 32(6):343-8. PubMed ID: 1490503
    [Abstract] [Full Text] [Related]

  • 10. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO.
    Eur Neurol; 1987 May 11; 27 Suppl 1():68-72. PubMed ID: 3428310
    [Abstract] [Full Text] [Related]

  • 11. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C, Romero S, de Medina O, Aljanati R, Scarmelli A, Caamano JL, Gonzales Panizza V.
    Eur Neurol; 1987 May 11; 27 Suppl 1():59-67. PubMed ID: 3428309
    [Abstract] [Full Text] [Related]

  • 12. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H.
    J Neurol; 1990 Feb 11; 237(1):24-8. PubMed ID: 2181074
    [Abstract] [Full Text] [Related]

  • 13. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C, Monreal A, Metzger B, Nilsen T.
    Eur Neurol; 2003 Feb 11; 49(1):39-44. PubMed ID: 12464717
    [Abstract] [Full Text] [Related]

  • 14. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN, Meerwaldt JD, Heersema T, van Manen J, Speelman JD.
    Eur Neurol; 1987 Feb 11; 27 Suppl 1():88-92. PubMed ID: 3322841
    [Abstract] [Full Text] [Related]

  • 15. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 16. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F, Meerwaldt JD, Man in 't Veld AJ, Hovestadt A, Schalekamp MA.
    Ann Neurol; 1989 Jun 11; 25(6):624-8. PubMed ID: 2742363
    [Abstract] [Full Text] [Related]

  • 17. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
    Malcolm SL, Allen JG, Bird H, Quinn NP, Marion MH, Marsden CD, O'Leary CG.
    Eur Neurol; 1987 Jun 11; 27 Suppl 1():28-35. PubMed ID: 3428307
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
    Kleedorfer B, Poewe W.
    J Neural Transm Park Dis Dement Sect; 1992 Jun 11; 4(2):173-8. PubMed ID: 1571080
    [Abstract] [Full Text] [Related]

  • 19. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
    Nordera GP, Lorizio A, Lion P, Durisotti C, D'Andrea G, Ferro-Milone F.
    Eur Neurol; 1987 Jun 11; 27 Suppl 1():76-80. PubMed ID: 3322839
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.